Amneal Pharmaceuticals (AMRX) News Today → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free AMRX Stock Alerts $6.71 +0.05 (+0.75%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 10:45 AM | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)May 9, 2024 | marketbeat.comLSV Asset Management Has $6.61 Million Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)LSV Asset Management decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 23.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,089,300 shares of thMay 8, 2024 | americanbankingnews.comThe Goldman Sachs Group Increases Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00May 8, 2024 | americanbankingnews.comTruist Financial Reiterates "Buy" Rating for Amneal Pharmaceuticals (NASDAQ:AMRX)May 6, 2024 | markets.businessinsider.comAssessing Amneal Pharmaceuticals: Insights From 4 Financial AnalystsMay 6, 2024 | finance.yahoo.comAmneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)May 6, 2024 | marketbeat.comThe Goldman Sachs Group Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00The Goldman Sachs Group upped their target price on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a "buy" rating in a report on Monday.May 6, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Reaffirmed by Truist FinancialTruist Financial restated a "buy" rating and issued a $9.00 target price (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research report on Monday.May 6, 2024 | markets.businessinsider.comAmneal Pharmaceuticals: A Strong Buy on Robust Growth and Promising PipelineMay 5, 2024 | americanbankingnews.comAmneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week High at $6.90May 4, 2024 | msn.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comAmneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 3, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High at $6.90Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High at $6.90May 3, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2024 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.530-0.630 for the period, compared to the consensus estimate of 0.580. The company also issued revenue guidance of $2.6 billionillion-$2.7 billionillion, compared to the consensus estimate of $2.6 billionillion.May 3, 2024 | msn.comGeneric Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit SettlementMay 3, 2024 | msn.comAmneal stock climbs on Q1 report, opioid settlement updateMay 3, 2024 | seekingalpha.comAmneal Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | msn.comAMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 3, 2024 | reuters.comDrugmaker Amneal agrees to $270 million U.S. opioid settlementMay 3, 2024 | washingtonpost.comAmneal: Q1 Earnings SnapshotMay 3, 2024 | businesswire.comAmneal Reports First Quarter 2024 Financial ResultsMay 2, 2024 | msn.comAmneal Pharmaceuticals Q1 2024 Earnings PreviewMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Amneal Pharmaceuticals (AMRX)April 30, 2024 | msn.comCalifornia is joining with a New Jersey company to make a generic opioid overdose reversal drugApril 30, 2024 | msn.comCalifornia teams with Amneal Pharma for cheaper, generic version of NarcanApril 29, 2024 | msn.comCalifornia is joining with a New Jersey company to buy a generic opioid overdose reversal drugApril 25, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Trading Down 7.1%Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 7.1%April 25, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Sells 146,925 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Allspring Global Investments Holdings LLC lessened its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 51.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 137,764 sharesApril 24, 2024 | marketwatch.comAmneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone SprayApril 24, 2024 | markets.businessinsider.comAmneal's OTC Naloxone Nasal Spray Receives FDA Approval For Opioid Overdose Emergency TreatmentApril 24, 2024 | businesswire.comAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseApril 16, 2024 | businesswire.comAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineApril 15, 2024 | finance.yahoo.comAmneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past weekApril 14, 2024 | marketbeat.comPhocas Financial Corp. Buys Shares of 714,890 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Phocas Financial Corp. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 714,890 shares of the company's stock, valued at approximately $4,339,0April 14, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 15.9% in MarchAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 2,400,000 shares, a growth of 15.9% from the March 15th total of 2,070,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 2.2% of the company's stock are sold short.April 11, 2024 | finance.yahoo.comAlkermes' Innovations Are Transforming Mental Health TreatmentsApril 10, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 1.9%Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 1.9%April 10, 2024 | businesswire.comAmneal to Report First Quarter 2024 Results on May 3, 2024April 9, 2024 | stocknews.com3 Lucrative Pharma Stocks to Diversify Your InvestmentsApril 9, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 2.2%Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 2.2%April 8, 2024 | msn.comBausch Health drops after suing Amneal Pharma over Xifaxan genericApril 8, 2024 | marketbeat.comVanguard Group Inc. Boosts Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Vanguard Group Inc. boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,548,300 shares of the company's stock after purchasing an additional 412April 7, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Position Decreased by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 71.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,045 shares of the companApril 5, 2024 | marketwatch.comBausch Health Sues Amneal Over IBS Treatment PatentApril 3, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Sees Strong Trading VolumeAmneal Pharmaceuticals (NASDAQ:AMRX) Sees Strong Trading VolumeMarch 28, 2024 | businesswire.comAmneal to Ring the Nasdaq Closing Bell on April 2, 2024March 27, 2024 | msn.comAmneal gains FDA greenlight to develop Ciprodex generic for ear infectionsMarch 25, 2024 | markets.businessinsider.comAmneal Pharma Receives FDA Approval For Ciprofloxacin And Dexamethasone Otic SuspensionMarch 25, 2024 | marketwatch.comAmneal Pharma Gets FDA Nod for Infection Fighting Drug CombinationMarch 25, 2024 | finance.yahoo.comAmneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career… Click For My #1 FREE Crypto for 2024 AMRX Media Mentions By Week AMRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼0.700.57▲Average Medical News Sentiment AMRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼73▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMPH News Today DCPH News Today RCKT News Today NAMS News Today ARDX News Today GLPG News Today SNDX News Today KROS News Today EWTX News Today AGIO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
